Gerald McMahon Ph.D. is Director at Celldex Therapeutics, Inc. (CLDX). They have made 6 open-market trades across 2 companies since 2008, most recently 2019-06-05.
CIK 0001290747
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $67K since 2008, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| HARP | BUY | 2019-05-14 | 2019-05-16 | $10.16 | $10K | +8.8% | +13.0% | +7.4% |
| HARP | BUY | 2019-05-08 | 2019-05-10 | $10.56 | $11K | +13.7% | +19.0% | +27.5% |
| HARP | BUY | 2019-05-03 | 2019-05-07 | $10.53 | $11K | +11.0% | +6.6% | +26.2% |
| PARD | BUY | 2008-12-30 | 2008-12-31 | $1.29 | $10K | N/A | N/A | N/A |
| PARD | BUY | 2008-12-29 | 2008-12-30 | $1.40 | $10K | N/A | N/A | N/A |
| PARD | BUY | 2008-03-06 | 2008-03-07 | $3.93 | $15K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.